International Clinical Trial: A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1%

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119741) titled 'A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1%' on March 3.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: PLA General Hospital

Condition: Non-Small Cell Lung Cancer

Intervention: Arm A:Sintilimab (200mg, Q3W) combined with ipilimumab N01 (1 mg/kg, Q6W) and chemotherapy (intravenously Q3W for 2 cycles) . In the maintenance therapy, Sintilimab (200mg, Q3W) combined with ipilimuma...